Stock comparison
Amicus Therapeutics
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
FOLD
Amicus Therapeutics
Market cap
$4.55B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | FOLD | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 42D | 77B | LMAT |
| Benjamin Graham | 66D | 89A | LMAT |
| Philip Fisher | 52C | 81C | LMAT |
| Peter Lynch | 54C | 67B | LMAT |
| Joel Greenblatt | 69C | 56D | FOLD |
| Charlie Munger | 41D | 68D | LMAT |
| Terry Smith | 37D | 69D | LMAT |
Side-by-side metrics
| Metric | FOLD | LMAT |
|---|---|---|
| Market cap | $4.55B | $2.23B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | 139.7x | 36.6x |
| ROIC (TTM) | -6.46% | 9.43% |
| Gross margin | 87.91% | 72.39% |
| Net margin | -4.27% | 24.35% |
| Revenue CAGR 5y | 20.03% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 1.8x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
FOLD leads on
- P/E (TTM)-vs 37.1x+122%
- Market cap$4.55Bvs $2.23B+51%
- Revenue CAGR 5y20.03%vs 12.75%+36%
- Gross margin87.91%vs 72.39%+18%
LMAT leads on
- Net margin24.35%vs -4.27%+118%
- ROIC (TTM)9.43%vs -6.46%+101%
- Dividend yield0.84%vs 0.0%+100%
- EV/EBIT36.6xvs 139.7x+74%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.